申请人:Sznaidman Marcos
公开号:US20110130559A1
公开(公告)日:2011-06-02
This application provides a process for preparing enantiomerically pure β-D-dioxolane nucleosides. In particular, a new synthesis of (−)-DAPD, suitable for large scale development, is described. In one embodiment the invention provides a process for preparing a substantially pure β-D- or β-L-1,3-dioxolane nucleosides comprising a) preparing or obtaining an esterified 2,2-dialkoxy ethanol; b) cyclizing the esterified 2,2-dialkoxy ethanol with glycolic acid to obtain a 1,3-dioxolane lactone; c) resolving the 1,3-dioxolane lactone to obtain a substantially pure D- or L-lactone; d) selectively reducing and activating the D- or L-chiral lactone to obtain a substantially pure D- or L-1,3-dioxolane; e) coupling the D- or L-1,3-dioxolane to an activated and/or protected purine or pyrimidine base; and f) optionally purifying the nucleoside to obtain a substantially pure protected β-D- or β-L-1,3-dioxolane nucleoside.
该应用程序提供了一种制备对映纯的β-D-二氧杂环己烷核苷的方法。特别地,描述了一种适用于大规模开发的(−)-DAPD的新合成方法。在一种实施例中,该发明提供了一种制备基本纯的β-D-或β-L-1,3-二氧杂环己烷核苷的方法,包括a) 准备或获得酯化的2,2-二烷氧基乙醇; b) 用乙醇酸环化酯化的2,2-二烷氧基乙醇以获得1,3-二氧杂环己烷内酯; c) 分离1,3-二氧杂环己烷内酯以获得基本纯的D-或L-内酯; d) 选择性还原和激活D-或L-手性内酯以获得基本纯的D-或L-1,3-二氧杂环己烷; e) 将D-或L-1,3-二氧杂环己烷偶联到活化和/或保护的嘌呤或嘧啶碱基上; f) 可选地纯化核苷酸以获得基本纯的保护的β-D-或β-L-1,3-二氧杂环己烷核苷。